Loading clinical trials...
Loading clinical trials...
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Dupilumab
Placebo (for Dupilumab)
Locations
93
United States
Anniston, Alabama, United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Bakersfield, California, United States
Costa Mesa, California, United States
Fremont, California, United States
Start Date
November 30, 2014
Primary Completion Date
October 31, 2015
Completion Date
January 31, 2016
Last Updated
June 2, 2020
NCT06488742
NCT05250115
NCT03563066
NCT04011215
NCT05014438
NCT04179760
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions